TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05957848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taken daily
Study: NCT06153238
Drug: GME751
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Q6W, i.v. infusion, over 24 weeks period
Study: NCT05411367
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye
Study: NCT04808622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo normal saline given as a one-time 7 mL one-time IV bolus injection
Study: NCT05765851
Drug: DS-1103a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Study: NCT05149365
Drug: Standard Prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
Study: NCT00104754
Drug: liposomal SN-38
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05889390
Drug: Cyclophosphamide/Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: according to the AC protocol
Study: NCT06549309
Drug: JMKX003801
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohort of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation.
Study: NCT06549309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohorts of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation.
Study: NCT04531215
Drug: ultrasound guided Erector Spinae Plane
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
Study: NCT05502380
Drug: Standard antibiotic prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection
Study: NCT04895306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly intramuscular administration of Placebo
Study: NCT04651361
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study: NCT05297513
Drug: ActiveMatrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
Study: NCT04861376
Drug: Pueraria lobata
Normalized name: PUERARIA LOBATA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
Study: NCT05756153
Drug: GFH925
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFH925 tablets administered orally daily.
Study: NCT06051344
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: . Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
Study: NCT05520827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00399230
Drug: Optive
Normalized name: optive
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03024177
Drug: Vapendavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapendavir Tablets, 264 mg
Study: NCT03024177
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapendavir 264 mg matching tablets
Study: NCT04874012
Drug: Active comparator Taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
Study: NCT05615532
Drug: LY3209590 (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05615532
Drug: LY3209590 (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT05638893
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablet/12hr) + celecoxib (200mg/day) for three months.
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg QD: WJ01024, Q4W, once per day
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg BID: WJ01024, Q4W, twice per day
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg BID: WJ01024, Q4W, twice per day
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg BIW: WJ01024, Q4W, twice per week
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg BIW: WJ01024, Q4W, twice per week
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg BIW: WJ01024, Q4W, twice per week
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg QW: WJ01024, Q4W, once per week
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg QW: WJ01024, Q4W, once per week
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg QW: WJ01024, Q4W, once per week
Study: NCT04991129
Drug: WJ01024
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg QW: WJ01024, Q4W, once per week
Study: NCT05033808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl is given once over 15 Minutes via a central line
Study: NCT05505006
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
Study: NCT06629402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive medication
Study: NCT05926505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
Study: NCT06629246
Drug: Conventional heart failure treatment
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition.
Study: NCT05145062
Drug: BIVV003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous administration
Study: NCT04140279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution, no active ingredient.
Study: NCT06629246
Drug: Pogejiuxin decoction combined with conventional heart failure treatment
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to receiving standard heart failure treatment, patients are also administered Pogejiuxin Decoction.The formula of Pogejiuxin Decoction is as follows : Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
Study: NCT05556356
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-operative acetaminophen (1000mg)
Study: NCT00381147
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04872660
Drug: Gushen Antai Pill
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
Study: NCT04872660
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
Study: NCT05101616
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
Study: NCT04845178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride, sterile, unpreserved, USP/PhEur
Study: NCT05838092
Drug: allo-APZ2-OTS
Normalized name: allo-2-hydroxycitric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
Study: NCT05838092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05608499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical does not contain active properties of study drug
Study: NCT05939466
Drug: Bedrocan®-type cannabis (22% THC, <1% CBD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoction with 100 mg of Bedrocan®-type cannabis (22% THC, \<1% CBD)
Study: NCT05678257
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT06576401
Drug: [14C] HDM1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05893381
Drug: [177Lu]Lu-PSMA I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
Study: NCT05861154
Drug: Benzocaine Gel
Normalized name: Benzocaine Gel
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a 20% Benzocaine topical anaesthetic gel will be applied. To increase the absorption of the topical anaesthetic gel, soft tissues will be dried with (2 x 2 cm) gauze. Topical anaesthetic gel will be applied at the site of needle penetration and left in contact with the soft tissues for one minute in order to to maximize its effect.
Study: NCT05327972
Drug: The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance.
Study: NCT04872881
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.
Study: NCT05755672
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines
Study: NCT05248139
Drug: Intraoperative delivery of medication, Kenalog (Triamcinolone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
Study: NCT05248139
Drug: Topical post-operative eyedrops, Prednisolone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
Study: NCT04924998
Drug: current treatment of AL-CM
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: current treatment of AL-CM
Study: NCT05328583
Drug: HRS5685；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H
Study: NCT06566586
Drug: TQB3702 tablets+Chemotherapy regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3702 tablets: Tyrosine kinase inhibitor；~Chemotherapy regimen：inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis；
Study: NCT04386642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline solution in a clear 50-ml syringe
Study: NCT04913649
Drug: Ferric Derisomaltose 100 MG/ML
Normalized name: ferric derisomaltose 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment with a single dose IVI (ferric derisomaltose), with a dose of 20mg/kg in approximately 60 minutes.
Study: NCT00416377
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04891484
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
Study: NCT04631549
Drug: SHR3680
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR3680, PO, single dose
Study: NCT05001854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg every 6 hours of placebo per os
Study: NCT05950113
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IV
Study: NCT04842383
Drug: Hemp Oil
Normalized name: HEMP OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
Study: NCT05186506
Drug: Ensatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg administered once daily orally for two years.
Study: NCT05186506
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ，until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
Study: NCT06726161
Drug: RYZ801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ac-225
Study: NCT05527483
Drug: [68Ga]PSMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
Study: NCT05527483
Drug: Flourine-18 [F-18] Sodium Fluoride (NaF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
Study: NCT05003713
Drug: CORT125236
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
Study: NCT05003713
Drug: Placebo matching CORT125236
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
Study: NCT06503029
Drug: Listeren Mouthwash
Normalized name: Listerine Mouthwash Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listeren Mouthwash is used as a cleaning method for orthodontic clear aligners. It includes Eucalyptol and Menthol as active ingredients.
Study: NCT05164627
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: After patient arrival at the PACU, Paediatric Anaesthesia Emergence Delirium (PAED) scale ,Ramsay sedation scores (RSS), emergence agitation, HR, and mean arterial blood pressure (MAP) were recorded every 5 min during the first 30 min, then every 10 min for the remaining 30 min of the recovery room stay. Patients were then transferred to the ward. All postoperative observations and scores were performed by the same anesthesiologist who was blinded to the group assignment
Study: NCT00120913
Drug: Birth control pills
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04536454
Drug: [18F]FPyGal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotracer for PET-imaging
Study: NCT04987658
Drug: OLZ/SAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine and Samidorphan taken once daily over a max period of 21 days
Study: NCT06034041
Drug: Mediclore
Normalized name: Medicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
Study: NCT06034041
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
Study: NCT04807335
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv single dose
Study: NCT06092931
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablets
Study: NCT06486974
Drug: NaF
Normalized name: Renaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
Study: NCT06486974
Drug: Na MFP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
Study: NCT05038969
Drug: Stomopral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule contains 40 mg Esomeprazole
Study: NCT04694027
Drug: VitaE
Normalized name: Oriental arborvitae pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin e 400 mg
Study: NCT06125782
Drug: Placebo of Omega-3 fatty acid softgel capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Omega-3 fatty acid softgel capsule- colour and shape almost similar to the original drug- 1 for children at or below 25 kg and 2 for above 25 kg.
Study: NCT06307795
Drug: ANS014004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varying doses of ANS014004
Study: NCT04705987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1c/24h Treatment 8 weeks
Study: NCT06650930
Drug: Oral calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants receive a single, open-label dose of oral calcium carbonate 3000mg
Study: NCT06091436
Drug: GenSci094
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
Study: NCT06091436
Drug: Placebo GenSci094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
Study: NCT04756648
Drug: CT0180 Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five dose levels were tentatively determined.
Study: NCT04894123
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil : 35 mg/m² orally twice a day from day 1 to day 5 every 14 days.~If oxaliplatin is stopped or it is not indicated, trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days.
Study: NCT06583330
Drug: Low Molecular Weight Heparin (dalteparin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.